Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada)

Background: Schizophrenia is a chronic debilitating disease that affects ~110,000 Canadians (0.55% lifetime prevalence). Risperidone long-acting injection (RLAI) is the first injectable, long-acting, atypical antipsychotic drug marketed in Canada. Objective: The aim of this study was to assess the c...

Full description

Saved in:
Bibliographic Details
Main Authors: Ganesan, Soma, McKenna, Mario, Procyshyn, Ric M., Zipursky, Sheldon
Format: Artigo
Language:Inglês
Published: Elsevier 2007
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3969908/
https://ncbi.nlm.nih.gov/pubmed/24692772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.curtheres.2007.12.002
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items